Cardiovascular Benefits That Support Safe Combination Therapy Research published in major cardiology journals shows that semaglutide reduces the risk of major adverse cardiovascular events (MACE) by approximately 26% in people with type 2 diabetes and established heart disease
Patients taking sulfonylureas, insulin, beta-blockers, diuretics, nonsteroidal anti-inflammatory drugs, statins, antidepressants, antipsychotics, or benzodiazepines should exercise caution when taking semaglutide as it may interact with these medications
Foundayo offers a convenient oral GLP-1 option, while Zepbound targets dual hormones for promising results
Research news A University of Texas at El Paso study has found that people with type 2 diabetes or obesity who used glucagon-like peptide-1 receptor agonists had lower odds of alcohol, opioid, nicotine and cocaine use disorders, although researchers said clinical trials were needed before the drugs could be considered for addiction treatment A study led by researchers at The University of Texas at El Paso, USA, has found that the use of diabetes and weight loss medicines such as Ozempic was associated with a lower risk of alcohol, opioid, nicotine and cocaine use disorders
Conflict of interest The authors declare that they have no conflicts of interest with the contents of this article